FOXO Technologies Announces New Series E Preferred Stock

An announcement from FOXO Technologies ( (FOXO) ) is now available.

On June 25, 2025, FOXO Technologies Inc. filed an amendment to its Certificate of Incorporation to authorize the issuance of up to 4,000,000 shares of a new Series E Cumulative Redeemable Secured Preferred Stock. This new series, announced on June 27, 2025, is intended to be used as an acquisition currency and capital raising security, with plans to publicly list it with its own trading symbol. The Series E Preferred Stock offers a 2.5% per annum cash dividend and a 5.0% per annum common stock dividend, secured by the stock of FOXO Acquisition Corporation. CEO Seamus Lagan highlighted that this move supports FOXO’s acquisition strategy, aiming to enhance net revenues and create long-term value for stockholders.

Spark’s Take on FOXO Stock

According to Spark, TipRanks’ AI Analyst, FOXO is a Underperform.

FOXO Technologies receives a low overall stock score primarily due to significant financial challenges, including continuous net losses, high debt, and negative cash flows. The technical analysis also suggests bearish momentum. Although valuation metrics are poor, recent corporate actions, such as acquisitions and restructuring, provide some hope for future improvement. However, these are not sufficient to outweigh the current financial and operational challenges facing the company.

To see Spark’s full report on FOXO stock, click here.

More about FOXO Technologies

FOXO Technologies Inc. operates in the healthcare and biotechnology industries, owning subsidiaries such as Rennova Community Health, Myrtle Recovery Centers, and FOXO Labs. These subsidiaries provide services ranging from hospital care and behavioral health treatment to biotechnology innovations aimed at improving human health and lifespan.

Average Trading Volume: 6,004,870

Technical Sentiment Signal: Sell

Current Market Cap: $2.22M

Find detailed analytics on FOXO stock on TipRanks’ Stock Analysis page.